[pubmed] The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis
Posté : 12 sept. 2020 12:00
Neuropharmacology. 2020 Sep 9:108303. doi: 10.1016/j.neuropharm.2020.108303. Online ahead of print.
ABSTRACT
The beneficial effects of acetylcholinesterase inhibitors for the treatment of myasthenia gravis (MG) was a major discovery that came about through one young physician putting together a string of previous observations. To understand how this discovery came to light, we must first go back to primitive times when men hunted by bow-and-arrow to capture their prey. This substance eventually was identified as curare. Centuries later, a connection was made between the physiological effects of curare and a disease entity with no known pathological mechanism or treatment, myasthenia gravis. In 1935, house officer Dr. Mary Walker was the first physician to try physostigmine in the treatment of MG, which had previously been used to treat curare poisoning. What she saw was a dramatic improvement in the symptoms experienced in patients with myasthenia gravis, and thus became the first documented case of use of physostigmine, an acetylcholinesterase inhibitor, in the treatment of myasthenia gravis. This article is a summary of the history of the use of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.
PMID:32918950 | DOI:10.1016/j.neuropharm.2020.108303
Source: https://pubmed.ncbi.nlm.nih.gov/3291895 ... 9&v=2.11.5